You are here: Home: Meet The Professors Vol. 1 2003: Case 4: Select publications

 

Select publications:
Addition of carboplatin to combination chemotherapy for the treatment of metastatic breast cancer

The addition of carboplatin to trastuzumab/paclitaxel improves efficacy in HER2- overexpressing metastatic breast cancer. Clin Breast Cancer 2003;3(6):378-80.

Alberti AM. A Phase II study of docetaxel (T) and carboplatin (CBP) as second line chemotherapy in metastatic breast cancer. Proc ASCO 2000:Abstract 438.

Brufsky AM et al. A phase II study of carboplatin and docetaxel as first line chemotherapy for metastatic breast cancer. Proc ASCO 2002:Abstract 2020.

Crown JP. The platinum agents: A role in breast cancer treatment? Semin Oncol 2001;28(1 Suppl 3):28-37. Abstract.

Donaldson LA et al. A phase I/II study of carboplatin, vinorelbine and capecitabine in patients with metastatic breast cancer. Proc ASCO 2002:Abstract 1960.

Franco S et al. Neoadjuvant (NEO) treatment of locally advanced and inflammatory breast cancer with weekly taxotere and carboplatin in tumors that do not overexpress HER-2. Proc ASCO 2002:Abstract 2048.

Hanna N et al. Phase I trial of carboplatin and paclitaxel with escalating doses of oral topotecan in patients with solid tumors. Am J Clin Oncol 2003;26(2):200-2. Abstract.

Kallab AK et al. A phase II study of weekly paclitaxel and carboplatin in metastatic breast cancer. Proc ASCO 2002:Abstract 1953.

Kosmas C et al. Phase I study of vinorelbine and carboplatin combination in patients with taxane and anthracycline pretreated advanced breast cancer. Oncology 2002;62(2):103-9. Abstract.

Loesch D et al. Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. J Clin Oncol 2002;20(18):3857-64. Abstract.

Martin M. Platinum compounds in the treatment of advanced breast cancer. Clin Breast Cancer 2001;2(3):190-208;discussion 209. Abstract.

Mavroudis D et al. Salvage treatment of metastatic breast cancer with docetaxel and carboplatin. A multicenter phase II trial. Oncology 2003;64(3):207-12.Abstract.

O'Rourke M et al. Efficacy and tolerability of a weekly taxol (T) plus carboplatin (C) regimen in patients <65 years versus ? years with advanced breast cancer (ABC). Proc ASCO 2002:Abstract 1967.Abstract.

Patton JF et al. Weekly paclitaxel, doxorubicin, and carboplatin in the treatment of metastatic breast cancer: A Minnie Pearl Research Network Phase II trial. Proc ASCO 2001:Abstract 2032.

Robert N et al. Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advanced breast cancer. Breast Cancer Res Treat 2002;Abstract 35.

Robert NJ et al. Toxicity profiles: A comparative study of Herceptin (trastuzumab) and taxol (paclitaxel) versus herceptin, taxol, and carboplatin in HER-2 positive patients with advanced breast cancer. Breast Cancer Res Treat 2001;Abstract 529.

Rodenhuis S et al. Randomized Phase III study of high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin in operable breast cancer with 4 or more axillary lymph nodes. Proc ASCO 2000:Abstract 286.

Slamon DJ et al. Phase II pilot study of herceptin combined with taxotere and carboplatin (TCH) in metastatic breast cancer (MBC) patients overexpressing the HER2-Neu protooncogene a pilot study of the UCLA Network. Proc ASCO 2001:Abstract 193.

Yardley DA et al. Final results of the Minnie Pearl Cancer Research Network first-line trial of weekly paclitaxel/carboplatin/trastuzumab in metastatic breast cancer. Breast Cancer Res Treat 2002;Abstract 439.

 

Table of Contents Top of Page 

 

Home · Search

 
CME Information
Faculty
Editor's Note
 
CASE 1: Disease recurrence and brachial plexopathy during the third trimester of pregnancy
- Select publications
 
CASE 2: Unresectable local recurrence in the pectoralis major after breast-conserving
surgery
- Select publications
 
CASE 3: Pulmonary metastases and mild shortness of breath
- Select publications
 
CASE 4: HER2-positive metastases to the lung and residual local breast cancer after lumpectomy
- Select publications
 
CASE 5: Liver metastases and mild hepatic encephalopathy
- Select publications
 
CASE 6: Ascites and pleural effusion ten years after primary breast cancer
- Select publications
Home · Contact us
Terms of use and general disclaimer